SHALBY2024-10-012024-12-31 SHALBY2024-10-012024-12-31 SHALBY2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member SHALBY2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member SHALBY2024-10-012024-12-31in-bse-fin:OneOperatingExpenses03Member SHALBY2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member SHALBY2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member SHALBY2024-10-012024-12-31in-bse-fin:FourOperatingExpenses03Member SHALBY2024-12-31 SHALBY2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue01Member SHALBY2024-10-012024-12-31in-bse-fin:OneReportableSegmentRevenue02Member SHALBY2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue01Member SHALBY2024-10-012024-12-31in-bse-fin:FourReportableSegmentRevenue02Member SHALBY2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults01Member SHALBY2024-10-012024-12-31in-bse-fin:OneReportableSegmentResults02Member SHALBY2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults01Member SHALBY2024-10-012024-12-31in-bse-fin:FourReportableSegmentResults02Member SHALBY2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets01Member SHALBY2024-10-012024-12-31in-bse-fin:OneReportableSegmentAssets02Member SHALBY2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member SHALBY2024-12-31in-bse-fin:OneReportableSegmentLiabilities01Member SHALBY2024-10-012024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member SHALBY2024-12-31in-bse-fin:OneReportableSegmentLiabilities02Member SHALBY2024-10-012024-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SHALBY2024-10-012024-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member SHALBY2024-10-012024-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member SHALBY2024-10-012024-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 540797 SHALBY NOTLISTED Shalby Limited Equity 2024-04-01 2025-03-31 2025-02-03 2025-01-28 INR Millions Third quarter 17:15:00 18:42:00 2025-02-03 2025-02-03 Not applicable Multi segment 2024-10-01 2024-12-31 Unaudited Consolidated 2756329000.00 54182000.00 2810511000.00 693567000.00 287212000.00 -317352000.00 478183000.00 106588000.00 163160000.00 1275648000.00 2687006000.00 123505000.00 0.00 123505000.00 131024000.00 22408000.00 153432000.00 0.00 -29927000.00 0.00 0.00 0.00 0.00 -29927000.00 -27520000.00 -57447000.00 0.00 0.00 0.00 0.00 1074870000.00 10 -0.28 -0.28 0.00 0.00 -0.28 -0.28 Notes to the Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2024 1. The above unaudited financial results for the quarter and nine months ended December 31, 2024 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors of the company at their respective meetings held on February 03, 2025. The Statutory Auditors of the Company have carried out a Limited Review for said unaudited financial results. 2.These financial results have been prepared in accordance with Indian Accounting Standards (Ind- AS) as prescribed under section 133 of Companies Act 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules 2015 and relevant amendment thereafter. 3. On January 15, 2025, Company launches India’s largest and Gujarat’s first Tissue and Bone Bank at Krishna Shalby hospital, Ahmedabad. The goal of launching Tissue and Bone bank is to improve the quality of life of patients across India by providing bone grafts that are reliable and affordable. 4.Shalby Limited Employees Welfare Trust has acquired 7,00,000 Equity Shares of Shalby Limited in June 2022 pursuant to Employee Stock Option Scheme-2021. During the quarter ended December 31, 2024, the Company has granted NIL Stock Options to eligible employees. Till December 31, 2024, Company has granted 4,94,735 Stock Options to eligible employees, out of which total 91,000 Stock Options were lapsed and 1,77,235 Options were exercised. 5. Shalby Limited has acquired 87.26% stake in shareholding of PK Healthcare Private Limited and hence it is a subsidiary of the Company Effective from 25th Janary, 2024. 6.Shalby Limited has acquired 100.00% stake in shareholding of Healers Hospital Private Limited and hence it is a subsidiary of the Company Effective from 15th March, 2024. 7. Shalby Advanced Technologies Inc. USA (step-down subsidiary of the Company) has incorporated its subsidiary in India namely Shalby Advanced Technologies India Pvt. Ltd on 11th April, 2024 8. The name of one of the subsidiary company has been changed from Mars Medical Devices Limited to Shalby Medtech Limited , effective from November 13, 2024. 9. The consolidated financial result includes the results of the Company and 14 Subsidiary companies (Covering 4 stepdown subsidiaies). The company together with its subsidiaries is herein referred to as the Group . 10.The higher effective tax rate in the consolidated financial statements is primarily due to the non-recognition of deferred tax assets in entities incurring losses, as a matter of prudence. 11. The Company is not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P /2018/144 dated 26th November, 2018. 12. The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits has received Presidential assent and has been published in the Gazette of India. However, the effective date of the Code and final rules for quantifying the financial impact are yet to be notified. The Group will assess the impact of the Code when relevant provisions are notified and will record related impact, if any, in the period the Code becomes effective. 13. As per Indian Accounting Standard ( Ind AS ) 108 - Segment Reporting , segment information has been provided in Consolidated Financial Results. The business segments of the company comprise of Healthcare Activities & Manufacturing of Implant. Disclosure for the same is given in the separate note. 14.Previous period figures have been re-grouped, re-cast and re-arranged wherever considered necessary to make it comparable. Multi segment 2024-04-01 2024-12-31 Unaudited Consolidated 8220624000.00 222749000.00 8443373000.00 1991303000.00 762865000.00 -685110000.00 1397750000.00 280434000.00 495310000.00 3636154000.00 7878706000.00 564667000.00 0.00 564667000.00 450022000.00 -26430000.00 423592000.00 0.00 141075000.00 0.00 0.00 0.00 0.00 141075000.00 -29747000.00 111328000.00 0.00 0.00 0.00 0.00 1074870000.00 10 1.31 1.31 0.00 0.00 1.31 1.31 Fees to Doctors and Consultants 641676000.00 Other Expenses 406926000.00 Other Operative Expenses 227046000.00 Fees to Doctors and Consultants 1922527000.00 Other Expenses 1011214000.00 Other Operative Expenses 702413000.00 Healthcare Services 2488570000.00 Manufacturing of Implants 267760000.00 Healthcare Services 7425290000.00 Manufacturing of Implants 795330000.00 2756330000.00 8220620000.00 2756330000.00 8220620000.00 Healthcare Services 204090000.00 Manufacturing of Implants -80590000.00 Healthcare Services 801700000.00 Manufacturing of Implants -237030000.00 123500000.00 564670000.00 a) The Healthcare Services segment includes business of setting up and managing hospitals and medical diagnostics services. b) The Manufacturing segment represents manufacturing of Implants. 123500000.00 564670000.00 Healthcare Services 14035590000.00 Manufacturing of Implants 3874510000.00 17910100000.00 Healthcare Services -3877160000.00 Manufacturing of Implants -3968110000.00 -7845270000.00 (i) Items that will not be reclassified to profit or loss 890000.00 (i) Items that will not be reclassified to profit or loss 2662000.00 890000.00 2662000.00 310000.00 930000.00 (i) Items that will be reclassified to profit or loss -28100000.00 (i) Items that will be reclassified to profit or loss -31479000.00 -28100000.00 -31479000.00 0.00 0.00